RESUMEN
Facial gender surgery (FGS) involves major surgical modification of the craniofacial soft tissues and skeleton. Computer-aided surgery (CAS) has improved precision and accuracy of osteotomies and decreased operative time in complex reconstructive craniofacial surgery. FGS is a natural application for CAS because the procedures are not only technically challenging but also demand a high standard of aesthetic results. Planning FGS cases virtually enables better and more reproducible results through simulated surgical planning and precise execution of osteotomies in surgical fields with limited exposure. We describe our experience with CAS in FGS for each of the facial thirds to introduce new concepts for conceptual planning of osteotomy design and patient-specific implants.
RESUMEN
BACKGROUND: The purpose of this work was to examine the ability of an oncolytic vaccinia virus expressing the human sodium iodine transporter (hNIS) to provide real time monitoring of viral therapy and effective treatment of malignant pleural mesothelioma (MPM). METHODS: Infectivity and cytotoxic effects of GLV-1h153 on mesothelioma cell lines of all histologic subtypes were assayed in vitro. Viral replication was examined by standard viral plaque assay. Orthotopic MPM xenografts were generated in athymic nude mice, treated with intrapleural GLV-1h153, and assessed for effect on tumor burden and survival. Orthotopic tumors were also imaged on single photon emission computed tomography (SPECT)/computed tomography (CT) after (131)I administration. RESULTS: GLV-1h153-infected and killed all cell lines in a time- and concentration-dependent manner. Viral replication demonstrated a >2.5-log increase in titer over 4 days. Intrapleural treatment of orthotopic MPM xenografts resulted in a significant decrease in tumor burden 1 week after treatment and an improvement in survival. Infection of orthotopic xenografts was both therapeutic and facilitated monitoring by (131)I-SPECT/CT via expression of hNIS in infected tissue. CONCLUSION: Our results suggest that GLV-1h153 may be a promising therapeutic agent for MPM and warrants further investigation.
